Literature DB >> 22203595

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

Chunfu Wang1, Lingling Jia, Haichang Huang, Dike Qiu, Lourdes Valera, Xin Huang, Jin-Hua Sun, Peter T Nower, Donald R O'Boyle, Min Gao, Robert A Fridell.   

Abstract

The antiviral profile of BMS-790052, a potent hepatitis C virus (HCV) replication complex inhibitor targeting nonstructural protein NS5A, is well characterized for HCV genotype-1. Here, we report that BMS-790052 inhibits hybrid replicons containing HCV genotype-4 NS5A genes with 50% effective concentrations (EC(50)s) ranging from 7 to 13 pM. NS5A residue 30 was an important site for BMS-790052-selected resistance in the hybrid replicons. Our results support the potential of BMS-790052 as a valuable component of combination therapy for HCV genotype-4 chronic infection.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203595      PMCID： PMC3294917          DOI： 10.1128/AAC.06169-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

Authors:  Mahmoud A Khattab; Peter Ferenci; Stephanos J Hadziyannis; Massimo Colombo; Michael P Manns; Piero L Almasio; Rafael Esteban; Ayman A Abdo; Stephen A Harrison; Nazir Ibrahim; Patrice Cacoub; Mohammed Eslam; Samuel S Lee
Journal:  J Hepatol       Date:  2010-12-08       Impact factor: 25.083

2.  Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay.

Authors:  Donald R O'Boyle; Peter T Nower; Julie A Lemm; Lourdes Valera; Jin-Hua Sun; Karen Rigat; Richard Colonno; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Authors:  Robert A Fridell; Dike Qiu; Chunfu Wang; Lourdes Valera; Min Gao
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

4.  Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

Authors:  Richard E Nettles; Min Gao; Marc Bifano; Ellen Chung; Anna Persson; Thomas C Marbury; Ronald Goldwater; Michael P DeMicco; Maribel Rodriguez-Torres; Apinya Vutikullird; Ernesto Fuentes; Eric Lawitz; Juan Carlos Lopez-Talavera; Dennis M Grasela
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

5.  Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Authors:  Robert A Fridell; Chunfu Wang; Jin-Hua Sun; Donald R O'Boyle; Peter Nower; Lourdes Valera; Dike Qiu; Susan Roberts; Xin Huang; Bernadette Kienzle; Marc Bifano; Richard E Nettles; Min Gao
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

6.  Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.

Authors:  Robert A Fridell; Dike Qiu; Lourdes Valera; Chunfu Wang; Ronald E Rose; Min Gao
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

7.  euHCVdb: the European hepatitis C virus database.

Authors:  Christophe Combet; Nicolas Garnier; Céline Charavay; Delphine Grando; Daniel Crisan; Julien Lopez; Alexandre Dehne-Garcia; Christophe Geourjon; Emmanuel Bettler; Chantal Hulo; Philippe Le Mercier; Ralf Bartenschlager; Helmut Diepolder; Darius Moradpour; Jean-Michel Pawlotsky; Charles M Rice; Christian Trépo; François Penin; Gilbert Deléage
Journal:  Nucleic Acids Res       Date:  2006-11-16       Impact factor: 16.971

Review 8.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

9.  Identification of hepatitis C virus NS5A inhibitors.

Authors:  Julie A Lemm; Donald O'Boyle; Mengping Liu; Peter T Nower; Richard Colonno; Milind S Deshpande; Lawrence B Snyder; Scott W Martin; Denis R St Laurent; Michael H Serrano-Wu; Jeffrey L Romine; Nicholas A Meanwell; Min Gao
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
  10 in total
  18 in total

1.  Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.

Authors:  Mengping Liu; Maria Tuttle; Min Gao; Julie A Lemm
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

2.  Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Authors:  Adel Abdel-Moneim; Alaa Aboud; Mohamed Abdel-Gabaar; Mohamed I Zanaty; Mohamed Ramadan
Journal:  Hepatol Int       Date:  2018-05-12       Impact factor: 6.047

Review 3.  Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.

Authors:  Evangelista Sagnelli; Mario Starace; Carmine Minichini; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Nicola Coppola
Journal:  Infection       Date:  2018-08-06       Impact factor: 3.553

Review 4.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

5.  Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

Authors:  Ruchi M Newman; Thomas Kuntzen; Brian Weiner; Andrew Berical; Patrick Charlebois; Carla Kuiken; Donald G Murphy; Peter Simmonds; Phil Bennett; Niall J Lennon; Bruce W Birren; Michael C Zody; Todd M Allen; Matthew R Henn
Journal:  J Infect Dis       Date:  2012-11-06       Impact factor: 5.226

6.  Synergistic Activity of Combined NS5A Inhibitors.

Authors:  Donald R O'Boyle; Peter T Nower; Min Gao; Robert Fridell; Chunfu Wang; Piyasena Hewawasam; Omar Lopez; Yong Tu; Nicholas A Meanwell; Makonen Belema; Susan B Roberts; Mark Cockett; Jin-Hua Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.

Authors:  David B Ascher; Jerome Wielens; Tracy L Nero; Larissa Doughty; Craig J Morton; Michael W Parker
Journal:  Sci Rep       Date:  2014-04-23       Impact factor: 4.379

Review 8.  Hepatitis C virus NS5A inhibitors and drug resistance mutations.

Authors:  Shingo Nakamoto; Tatsuo Kanda; Shuang Wu; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

9.  In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.

Authors:  Chunfu Wang; Lourdes Valera; Lingling Jia; Melissa J Kirk; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

10.  Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Authors:  Chunfu Wang; Lingling Jia; Donald R O'Boyle; Jin-Hua Sun; Karen Rigat; Lourdes Valera; Peter Nower; Xin Huang; Bernadette Kienzle; Susan Roberts; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.